John Fruge, MD
Pain Medicine · Lafayette, LANPI 1154862480
Payments from drug & device makers
What this record shows
14 manufacturers reported payments, led by Boston Scientific at 42.4% of the total.
Across 59 payments — averaging $70.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Stryker$856
- Abbott$483
- Saluda Medical Americas, Inc.$294
- SPR Therapeutics, Inc$278
- Globus Medical$149
- plus $326 from 8 others
What the payments were for
- Travel & lodging$1,69141%
- Food & beverage$2,44959%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 16 | $1,754 |
| Stryker | 12 | $856 |
| Abbott | 4 | $483 |
| Saluda Medical Americas, Inc. | 3 | $294 |
| SPR Therapeutics, Inc | 7 | $278 |
| Globus Medical | 3 | $149 |
| Medtronic | 5 | $109 |
| Zynex Medical, Inc. | 1 | $60 |
| Pacira Pharmaceuticals Incorporated | 2 | $39 |
| Nevro Corp. | 1 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Fidia Pharma USA Inc. | 1 | $17 |
| Vertex | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Superion Indirect Decompression System$1,067
- SPINEJACK$610
- ETERNA$465
- GENERAL - THERAPIES$203
- Evoke SCS$167
- Intracept$148
- Vyrsa V1$106
How this compares
$4,140 in reported general payments places this provider in the 55th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 100 | $1,469 |
| Gabapentin | 116 | $1,313 |
| Pregabalin | 38 | $1,230 |
| Tizanidine Hcl | 114 | $713 |
| Celecoxib | 62 | $651 |
| Duloxetine Hcl | 43 | $510 |
| Nortriptyline Hcl | 39 | $297 |
| Diclofenac Sodium | 18 | $246 |
| Tramadol Hcl | 60 | $192 |
| Meloxicam | 44 | $100 |
| Cyclobenzaprine Hcl | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Lafayette
- James RabalaisLafayette$10K
- Joseph GillespieLafayette$8K
- John MartinLafayette$3K
- Thomas MyersMandeville$118K
- Alan KayeNew Orleans$76K
- Derrick DeanTerrytown$68K
- Hazem EissaNew Orleans$50K
- Robert OwensNew Orleans$47K
- Gassan ChaibanLake Charles$30K
- Yashar EshraghiNew Orleans$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.